APEX1 and Down syndrome: Also, talazoparib and APE inhibitor III shows remarkable antileukemia effect, meanwhile, low dose of talazoparib and APE inhibitor can enhance the cytotoxicity of decitabine inmyelodysplastic syndromes/chronic myelomonocytic leukemia and acute myeloid leukemia (139).